iShares iBoxx $ Inv Grade Corporate Bond ETF vs Teladoc Health Inc — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while Teladoc Health Inc trades at $5.77 (market cap $1.01B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 28.2× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Teladoc Health Inc for 39 Days on average.
| LQD | TDOC | |
|---|---|---|
Market Cap | $28.50B | $1.01B |
Volume | 37,320,110 | 4,668,477 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $9.72 |
52-Week Low | $101.83 | $4.47 |
Typical Hold Time | 125 Days | 39 Days |
Enterprise Value | — | $1.27B |
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September and concerns about investment-grade corporate bonds as Treasury yields reach multi-decade highs.
The outlook remains cautious given the bearish technical setup and rising bond yields pressuring corporate debt valuations. Key risks include continued bond market volatility and higher borrowing costs for issuers. Investment opportunities exist for income-focused investors seeking 4.8% yield exposure to high-quality corporate bonds, though near-term pressure may persist.
TDOC trades at $5.54, down 0.36% on the day, with a bearish technical signal and mixed earnings history. The company reported revenue of $2.53B in 2025 but a net loss of $200.32M, reflecting ongoing profitability challenges. Analyst consensus is a 'Hold' with a $8.83 price target, indicating potential upside. Recent news includes a CFO transition and legal investigations, adding to investor uncertainty.
The outlook remains cautious due to persistent losses and competitive pressures, though valuation metrics like P/S of 0.4 and EV/EBITDA of 5.89 suggest the stock is undervalued. Key risks include weak cash flow trends and BetterHelp segment volatility. Upside depends on execution in integrated care and cost management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →